Abstract:Rationale: To ensure that quality medicines are available to the populace. Aim and objective: To provide a new perspective for drug sampling and testing using a risk-based approach globally, and provide a reference for improving the efficiency of the drug sampling and testing programme in China. Method: This study used a combination of theoretical analysis and problem analysis. First, we analysed the high-risk drugs that should be given attention to theoretically in the drug sampling testing programme based on the healthcare reform in China. Second, this study leveraged on data on the sampling and testing of drugs extracted from self-constructed data by the China Food and Drug Administration (CFDA). The integrated and structured data sets were used to conduct an innovative analysis that identifies the actual content of the drug sampling and testing programme and contrasts them with the theoretical content to understand the problems. This study used quantitative and qualitative approaches for data analysis. Results: Following analysis, we discovered that there is still a big gap between the reality of drug sampling and testing in China and the ideal state of the objective requirements of healthcare reforms. The major sources of risk are the retail pharmacies or hospital pharmacies in the distribution chain of drugs; however, the CFDA sampled mostly drugs from drug manufacturers. Additionally, the CFDA did not sample adequate essential medicines, bid-winning drugs (especially those with large price drops in centralized procurement), biological products and other high-risk drug varieties. The high-risk drugs produced by companies or enterprises with a history of noncompliance, especially bid-winning enterprises in centralized procurement, were not sampled. Conclusion: We suggest that the major content of drug sampling and testing in China should focus on the link of drug utilization, varieties of drugs with large price drops in centralized procurement and bid-winning enterprises with a history of noncompliance.

Comparative analysis of consistency evaluation for generic drugs in foreign countries

Study on Enterprise Strategies for the Evaluation of Quality and Efficacy Consistency of Generic Drugs

Literature analysis on pharmaceutical care in China

Has the consistency evaluation policy of generic drugs promoted the innovation quality of Chinese pharmaceutical manufacturing industry? An empirical study based on the difference-in-differences model

A consistency evaluation based on Chinese literatures for generic metformin hydrochloride

Literature Analysis on Drug introducing Management in Foreign hospitals

Comparison and Analysis of the Health Products Supervisions in China,Japan,USA and EU

基于一致性评价理念的药剂学实验教学的探讨 Discussion on Experimental Teaching of Pharmaceutics Based on the Concept of Consistency Evaluation

Research of Present Domestic Situation on Off-patent Originals and Generics

[Research on evaluation criteria over quality as core index of high grade Chinese patent medicine]

Evaluation on administration off-label drug use at home and abroad

Comparison on Definitions of Counterfeit or Substandard Drugs in Several Countries throughout the World

Quality Consistency Evaluation of Traditional Chinese Medicines: Current Status and Future Perspectives

Quality consistency evaluation between dispensing granules and traditional decoction of Gardeniae Fructus based on chemical similarity and bioequivalence

A Comparative Analysis of Generic Drug Assessment and Regulatory Approval in the USA, Europe and India

Analysis of provincial centralized bidding and procurement of drugs in China

The structural diversity of ibuprofen sustained-release pellets on the same goal of bioequivalence consistency

COMPARISON BETWEEN GENERIC DRUGS AND BRAND NAME DRUGS FROM BIOEQUIVALENCE AND THERMOEQUIVALENCE PROSPECTIVE

Analysis of Factors Related to Variation in Dissolution Profiles Estimated from Continuously Conducted Dissolution Tests of Generic Products

Analysis of the problems of drug sampling and testing programme under tripartite system reform in China

Comparision and Analysis on the Safety Issues of Gatifloxacin in Home and Abroad